During the India Pharma 2026 event on April 13, Union Minister J P Nadda outlined a roadmap for India to become a leader in the global pharmaceutical industry, particularly in biologics and specialty medicines. He stated that India's reputation as the 'pharmacy of the world' stems from its dominance in affordable generic medicines. Nadda emphasized the need for stronger research capabilities, increased investments, and greater industry participation to adapt to the rapidly changing pharmaceutical landscape. The government has introduced several initiatives, including the Biopharma SHAKTI programme, which allocates ₹10,000 crore (approximately $1.2 billion USD) over five years to enhance India's global pharmaceutical standing. Minister of State Anupriya Patel added that the government supports domestic manufacturers in transitioning towards biosimilars and innovative drug development. Furthermore, plans to establish a network of 1,000 clinical trial sites and integrate artificial intelligence into drug discovery processes were announced, aiming to position India as a preferred hub for drug development.